Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors (Q26823023)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

4 references

26 October 2020

23 November 2020

24 January 2021

28 January 2021

Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

28 September 2019

1 reference

2 October 2019

immunosuppressive drug

1 reference

26 October 2020

adverse drug reaction

1 reference

23 November 2020

kidney transplantation

1 reference

Serine/threonine-protein kinase TOR

24 January 2021

1 reference

28 January 2021

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Paolo Ria

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Simona Granata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Paola Tomei

2

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Luigino Boschiero

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Antonio Lupo

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

1 reference

19 September 2013

9 references

1 July 2019

25 June 2019

28 September 2019

2 October 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

26 October 2020

23 November 2020

24 January 2021

28 January 2021

Clinical and Developmental Immunology

10 references

1 July 2019

25 June 2019

28 September 2019

2 October 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

26 October 2020

23 November 2020

24 January 2021

28 January 2021

2013

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

403280

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

28 February 2020

copyright license

8 references

1 July 2019

25 June 2019

28 September 2019

2 October 2019

26 October 2020

23 November 2020

24 January 2021

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

28 January 2021

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Interstitial pneumonitis as an adverse reaction to mTOR inhibitors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Cardiovascular risk reduction in renal transplantation. Strategies for success

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Upstream and downstream of mTOR

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Banting lecture 1988. Role of insulin resistance in human disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus induced granulomatous interstitial pneumonitis.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Adverse events associated with mTOR inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Folate-conjugated rapamycin slows progression of polycystic kidney disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

New-onset diabetes after renal transplantation: risk assessment and management

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Prevention of cardiovascular disease in adult recipients of kidney transplants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Metabolic syndrome in kidney transplantation: management of risk factors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Common toxicities of mammalian target of rapamycin inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

mTOR, cancer and transplantation.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Pottransplantation anemia: management and rationale

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus in renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus upregulates aP2 expression in human monocytes and macrophages

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus-associated pulmonary toxicity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus-associated diffuse alveolar hemorrhage

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Tuberous sclerosis: from tubers to mTOR.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Enhancement of human platelet aggregation and secretion induced by rapamycin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Targeting mTOR pathway: A new concept in cancer therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Diffuse alveolar hemorrhage induced by everolimus

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

31 May 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

mTOR inhibitors and autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Severe everolimus-associated pneumonitis in a renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Hypersensitivity pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Prevalence and management of anemia in renal transplant recipients: a European survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Anemia following renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Anemia characteristics after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Predictive factors of anemia within the first year post renal transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Sirolimus interferes with iron homeostasis in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

mTOR inhibition and erythropoiesis: microcytosis or anaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Prognostic value of the metabolic syndrome in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Insulin resistance and risk of chronic kidney disease in nondiabetic US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

A central body fat distribution is related to renal function impairment, even in lean subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Severe limb lymphedema in sirolimus-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Generalized lymphedema in a sirolimus-treated renal transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Lymphedema associated with sirolimus in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Testosterone concentrations and sirolimus in male renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

The effect of sirolimus on sex hormone levels of male renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Rapamycin-induced oligospermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Sirolimus may reduce fertility in male renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Immunosuppressive agents and bone disease in renal transplant patients with hypercalcemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Bone mineral density and fracture prevalence in long-term kidney graft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Rates of first infection following kidney transplant in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Immunosuppressive therapy and infection after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Gastrointestinal leukocytoclastic vasculitis: an adverse effect of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F403280

Management of side effects of sirolimus therapy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Sirolimus-induced interstitial pneumonitis in a renal transplant recipient.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789319

Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine

28 November 2018

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis

1 reference

12 December 2020

Factors affecting erythropoietin production and correction of anemia in kidney transplant recipients

1 reference

12 December 2020

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

1 reference

12 December 2020

Everolimus-induced lymphedema in a renal transplant recipient: a case report

1 reference

12 December 2020

Serum ferritin levels after renal transplantation: a prospective study

1 reference

12 December 2020

Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat

1 reference

12 December 2020

Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine

1 reference

12 December 2020

Lymphedema: an unusual complication of sirolimus therapy

1 reference

12 December 2020

Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine

1 reference

12 December 2020

Post-transplant hypophosphatemia

1 reference

12 December 2020

Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin)

1 reference

12 December 2020

Evidence that rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes

1 reference

12 December 2020

Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study

1 reference

12 December 2020

Rapamycin's effect on vasomotion in the rat

1 reference

12 December 2020

Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients

1 reference

12 December 2020

Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function

1 reference

12 December 2020

Anemia: A Continuing Problem Following Kidney Transplantation

1 reference

12 December 2020

Identifiers

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24151517%20AND%20SRC:MED&resulttype=core&format=json